117 related articles for article (PubMed ID: 27268592)
1. Bacteremia due to ESKAPE pathogens: An emerging problem in cancer patients.
El-Mahallawy HA; Hassan SS; El-Wakil M; Moneer MM
J Egypt Natl Canc Inst; 2016 Sep; 28(3):157-62. PubMed ID: 27268592
[TBL] [Abstract][Full Text] [Related]
2. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistance of ESKAPE group-microorganisms in health institutions from Hermosillo and Ciudad Obregón, Sonora, México.
Álvarez-Ainza ML; Fong-Coronado PA; Ruiz-Bustos E; Castillón-Campaña LG; Quintero-Reyes IE; Duarte-Zambrano LA; Bolado-Martínez E
Front Cell Infect Microbiol; 2024; 14():1348093. PubMed ID: 38516533
[TBL] [Abstract][Full Text] [Related]
5. Antarctic Marine Bacteria as a Source of Anti-Biofilm Molecules to Combat ESKAPE Pathogens.
Artini M; Papa R; Vrenna G; Trecca M; Paris I; D'Angelo C; Tutino ML; Parrilli E; Selan L
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887257
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Enterococcus , Staphylococcus aureus , Klebsiella , Acinetobacter , Pseudomonas , and Enterobacter Species Transmission in the Pediatric Anesthesia Work Area Environment With and Without Practitioner Use of a Personalized Body-Worn Alcohol Dispenser.
Fernandez PG; Dexter F; Brown J; Whitney G; Koff MD; Cao S; Loftus RW
Anesth Analg; 2024 Jan; 138(1):152-160. PubMed ID: 36623234
[TBL] [Abstract][Full Text] [Related]
7. Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia.
Sirijatuphat R; Sripanidkulchai K; Boonyasiri A; Rattanaumpawan P; Supapueng O; Kiratisin P; Thamlikitkul V
PLoS One; 2018; 13(1):e0190132. PubMed ID: 29298323
[TBL] [Abstract][Full Text] [Related]
8. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
Ma YX; Wang CY; Li YY; Li J; Wan QQ; Chen JH; Tay FR; Niu LN
Adv Sci (Weinh); 2020 Jan; 7(1):1901872. PubMed ID: 31921562
[TBL] [Abstract][Full Text] [Related]
9. Essential Metabolic Routes as a Way to ESKAPE From Antibiotic Resistance.
Barra ALC; Dantas LOC; Morão LG; Gutierrez RF; Polikarpov I; Wrenger C; Nascimento AS
Front Public Health; 2020; 8():26. PubMed ID: 32257985
[TBL] [Abstract][Full Text] [Related]
10. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.
Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q
ACS Infect Dis; 2024 Jun; ():. PubMed ID: 38866389
[TBL] [Abstract][Full Text] [Related]
11. Rosin as a Natural Alternative for the effective disinfection of ESKAPE Pathogens and Clostridioides difficile spores.
Bell S; Thompson TP; Marks N; Fairley D; Kettunen H; Vuorenmaa J; Orte J; Gilmore BF; McGrath JW
J Appl Microbiol; 2024 Jan; ():. PubMed ID: 38244225
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of antimicrobial peptides against ESKAPE pathogens.
Roque-Borda CA; Primo LMDG; Franzyk H; Hansen PR; Pavan FR
Heliyon; 2024 Jun; 10(11):e31958. PubMed ID: 38868046
[TBL] [Abstract][Full Text] [Related]
13. Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development.
Neff SL; Hampton TH; Koeppen K; Sarkar S; Latario CJ; Ross BD; Stanton BA
mSystems; 2023 Dec; 8(6):e0065323. PubMed ID: 37975659
[TBL] [Abstract][Full Text] [Related]
14. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Miller WR; Arias CA
Nat Rev Microbiol; 2024 Jun; ():. PubMed ID: 38831030
[TBL] [Abstract][Full Text] [Related]
15. ESKtides: a comprehensive database and mining method for ESKAPE phage-derived antimicrobial peptides.
Wu H; Chen R; Li X; Zhang Y; Zhang J; Yang Y; Wan J; Zhou Y; Chen H; Li J; Li R; Zou G
Database (Oxford); 2024 Mar; 2024():. PubMed ID: 38531599
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic, genotypic, and metabolic resistance mechanisms of ESKAPE bacteria to chemical disinfectants: a systematic review and meta-analysis.
Chegene Lorestani R; Shojaeian A; Rostamian M
Expert Rev Anti Infect Ther; 2023; 21(10):1097-1123. PubMed ID: 37674347
[TBL] [Abstract][Full Text] [Related]
17. The burden of hospital acquired infections and antimicrobial resistance.
Abban MK; Ayerakwa EA; Mosi L; Isawumi A
Heliyon; 2023 Oct; 9(10):e20561. PubMed ID: 37818001
[TBL] [Abstract][Full Text] [Related]
18. Animal Models in the Evaluation of the Effectiveness of Phage Therapy for Infections Caused by Gram-Negative Bacteria from the ESKAPE Group and the Reliability of Its Use in Humans.
Cieślik M; Bagińska N; Górski A; Jończyk-Matysiak E
Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33498243
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the contribution to intraoperative pathogen transmission from bacterial contamination of patient nose, patient groin and axilla, anesthesia practitioners' hands, anesthesia machine, and intravenous lumen.
Dexter F; Loftus RW
J Clin Anesth; 2024 Feb; 92():111303. PubMed ID: 37875062
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
